



Health Advisory Committee Meeting Agenda

July 16, 2025, 6:00 p.m.

Livingston County Administration Building
304 E. Grand River, Conference Room 1, Howell, MI 48843

Pages

1. Call Meeting to Order

2. Roll Call

3. Approval of Agenda

4. Approval of Minutes

4.1 Meeting Minutes dated: June 17, 2025

1

5. Call to the Public

6. Reports

6.1 Solar Power

6.2 Opioid Use Prevention

Survey Rollout

6.3 Presentation from HAC to Board of Commissioners

7. New Business

8. Adjournment

Health Advisory Committee

Meeting Minutes



June 17, 2025, 6:00 p.m.
Livingston County Administration Building
304 E. Grand River, Conference Room 1, Howell, MI 48843

Voting Members Present: Nancy McGuire, Holly Austin, Dawn Smith

Voting Members Absent: Thomas Latchney, Lee Ann Blazejewski

Non-Voting Members Lindsay Kalberer, Wes Nakagiri
Absent:

1. Call Meeting to Order

The meeting was called to order by the Committee Chair, D. Smith, at 6:06 p.m.

2. Roll Call

Roll call by the recording secretary indicated the presence of a quorum.

3. Approval of Agenda

Motion to approve the agenda as presented.

Moved by: N. McGuire

Seconded by: H. Austin

Yes (3): N. McGuire, H. Austin, and D. Smith; No (0): None;

Absent (2): T. Latchney, and L. Blazejewski

Motion Carried (3-0-2)

4. Approval of Minutes

4.1 Meeting Minutes dated: May 21, 2025

Motion to approve the minutes as presented.

Moved by: N. McGuire

Seconded by: H. Austin

Yes (3): N. McGuire, H. Austin, and D. Smith; No (0): None;

Absent (2): T. Latchney, and L. Blazejewski

Motion Carried (3-0-2)

5. Call to the Public

None.

6. Reports

6.1 Solar Power

The Cohoctah Township Board of Trustees/Supervisor Mark Fosdick raised several health-related concerns, including potential impacts from noise levels and the

psychological effects of visual aesthetics. These concerns were presented as compelling and worthy of further examination.

The Director/Health Officer of the Livingston County Health Department Matt Bolang addressed logistical challenges, noting that any action items endorsed by the Health Advisory Committee and the Livingston County Board of Commissioners may require additional funding and staffing. He also expressed his view that the health concerns may not be substantiated and cautioned that invoking Public Act 233 for this purpose could risk diluting the intended use of the legislation.

6.2 MRNA Vaccine Statement

Moved by: N. McGuire
Seconded by: D. Smith

Motion to approve the (attached Exhibit A) MRNA Vaccine Statement as amended to be placed on the Health Advisory Committee's website.

Yes (3): N. McGuire, H. Austin, and D. Smith; No (0): None;
Absent (2): T. Latchney, and L. Blazejewski

Motion Carried (3-0-2)

6.3 Opioid Use Prevention

a. Survey Questions

Discussion related to the survey tool. Support for adding website to the end of the survey tool for participants to find more information as linked to our Health Advisory Committee Webpage.

Moved by: N. McGuire
Seconded by: D. Smith

Motion to approve the (attached Exhibit B) MDHHS Nonopioid Directive Healthcare provider survey as amended to be sent out to the Livingston County Listserv of all advanced Health Care Providers in Livingston County to raise awareness and gather data.

Yes (3): N. McGuire, H. Austin, and D. Smith; No (0): None;
Absent (2): T. Latchney, and L. Blazejewski

Motion Carried (3-0-2)

6.4 Replication of Vaccine Study

Tabled due to major changes occurring at the federal level.

6.5 Gender Treatment

Tabled to gather more data.

7. New Business

H. Austin brought up need to compile all data for the upcoming July Board of Commissioners meeting to indicate what needs to be presented to the board. H. Austin to work on presentation to review with Health Advisory Committee at the July 16 meeting in anticipation of presenting at the Board of Commissioners meeting July 28, 2025. Board of Commissioners Presentation will need to be added to the July Agenda.

8. Adjournment

Motion to adjourn the meeting at 7:12 p.m.

Moved by: D. Smith

Seconded by: H. Austin

Yes (3): N. McGuire, H. Austin, and D. Smith; No (0): None;

Absent (2): T. Latchney, and L. Blazejewski

Motion Carried (3-0-2)

Holly Austin, Recording Secretary

UNAPPROVED

Health Advisory Committee Position Statement on COVID-19 Vaccination in Healthy Populations**Date:** June 17, 2025**Committee:** Health Advisory Committee**Summary:**

After a comprehensive review of current data and scientific literature, the Health Advisory Committee has determined that we **do not recommend routine COVID-19 vaccination for healthy individuals**, including:

- Infants and young children
- Adolescents
- Pregnant women
- Otherwise healthy adults without underlying risk factors
- Individuals with underlying health conditions should consult with their advanced healthcare provider.

Rationale:**1. Risk-Benefit Assessment**

Available data suggest that for healthy individuals—particularly children, adolescents, and pregnant women—the risk of severe illness or complications from COVID-19 is low. Conversely, reported adverse events, though rare, present a level of risk that may outweigh the expected benefits in these lower-risk groups.

2. Efficacy Concerns in Preventing Transmission

Current evidence indicates that while COVID-19 vaccines reduce the risk of severe disease in vulnerable populations, their ability to prevent infection or onward transmission is limited, particularly with emerging variants.

3. Limited Long-Term Safety Data

Longitudinal safety data for newer mRNA vaccines, especially in healthy pediatric and prenatal populations, remain limited. The absence of long-term data restricts our ability to fully assess risks in these groups.

4. Alternative Strategies

For healthy populations, we recommend continuing with risk-reduction strategies such as maintaining general hygiene, supporting natural immunity where

MDHHS 5793 Nonopioid Directive Prescriber Survey**Introduction:**

The Michigan Department of Health and Human Services (MDHHS) developed form 5793, the Nonopioid Directive, to allow patients to decline the offer or administration of opioids. Your feedback will help us understand prescriber awareness and usage of this form and identify areas where further education or support may be helpful.

Section 1: Prescriber Information

1. **What is your professional role?**
 - ☐ Physician (MD/DO)
 - ☐ Physician Assistant (PA)
 - ☐ Nurse Practitioner (NP)
 - ☐ Dentist
 - ☐ Other (please specify): _____
 2. **In which type of practice setting do you primarily work?**
 - ☐ Primary Care
 - ☐ Emergency Medicine
 - ☐ Surgical Specialty
 - ☐ Pain Management
 - ☐ Dentistry
 - ☐ Other (please specify): _____
 3. **How many years have you been in practice?**
 - ☐ Less than 5 years
 - ☐ 5–10 years
 - ☐ 11–20 years
 - ☐ More than 20 years
-

Section 2: Awareness and Knowledge of the Nonopioid Directive

4. **Prior to this survey, were you aware of the MDHHS Nonopioid Directive (form 5793)?**
 - ☐ Yes
 - ☐ No

5. **How familiar are you with the content and purpose of the Nonopioid Directive?**
- ☐ Very familiar
 - ☐ Somewhat familiar
 - ☐ Slightly familiar
 - ☐ Not familiar at all
6. **Where did you first learn about the Nonopioid Directive?** (Check all that apply)
- ☐ MDHHS website
 - ☐ Professional organization or society
 - ☐ Colleague or peer
 - ☐ Continuing education or training
 - ☐ Employer or health system
 - ☐ I have not heard of it
 - ☐ Other (please specify): _____
-

Section 3: Understanding and Use

7. **To what extent do you understand when and how to use the Nonopioid Directive form?**
- ☐ Completely understand
 - ☐ Mostly understand
 - ☐ Somewhat understand
 - ☐ Do not understand
8. **Have you ever provided the Nonopioid Directive form to a patient?**
- ☐ Yes
 - ☐ No
9. **If yes, approximately how often do you offer this form?**
- ☐ With every patient encounter where opioids may be discussed or prescribed
 - ☐ Only upon patient request
 - ☐ Occasionally, based on clinical judgment
 - ☐ Rarely
 - ☐ Other (please specify): _____
10. **If no, what are the main reasons you have not offered the form?** (Check all that apply)
- ☐ I was not aware of it
 - ☐ I am unsure how or when to use it
 - ☐ It is not part of our clinical workflow

- ☐ I do not believe it is necessary
 - ☐ Time constraints
 - ☐ Other (please specify): _____
-

Section 4: Attitudes and Implementation

11. **Do you believe the Nonopioid Directive is a helpful tool for patient-centered care?**
- ☐ Strongly agree
 - ☐ Agree
 - ☐ Neutral
 - ☐ Disagree
 - ☐ Strongly disagree
12. **Would you support incorporating the Nonopioid Directive into your organization's standard intake or consent processes?**
- ☐ Yes
 - ☐ No
 - ☐ Unsure
13. **What barriers do you foresee (or have encountered) in implementing the Nonopioid Directive in your practice?**
- Open-ended response: _____
14. **What additional resources would help you more effectively use the Nonopioid Directive? (Check all that apply)**
- ☐ Brief training or webinar
 - ☐ Printed educational materials
 - ☐ Integration into EHR system
 - ☐ Patient education handouts
 - ☐ Technical assistance from MDHHS
 - ☐ Other (please specify): _____
-

Section 5: Final Thoughts

15. **Do you have any suggestions for improving awareness or usability of the Nonopioid Directive?**
- Open-ended response: _____

16. For more information regarding the MDHHS 5793 Nonopioid Directive, please visit the Livingston County Health Advisory Committee website at the following link: <https://milivcounty.gov/boc/boards-committees/health-advisory-committee/health-information/>